Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States

Stefan K. Barta, Nicholas Liu, Maral DerSarkissian, Rose Chang, Mingchen Ye, Mei Sheng Duh, Andy Surinach, Michelle A. Fanale, Kristina S. Yu

Blood (2022) 140 (Supplement 1): 5167–5169.

https://doi.org/10.1182/blood-2022-162375

Published: 2022

Journal Articles

Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)

Mayur Narkhede, Nicholas Liu, Andy Surinach, Michelle A. Fanale, Kristina S. Yu, Allison Winter

Blood (2022) 140 (Supplement 1): 10798–10800.

https://doi.org/10.1182/blood-2022-162603

Published: 2022

Journal Articles

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database

Allison Winter, Nicholas Liu, Andy Surinach, Michelle A. Fanale, Kristina S. Yu, Mayur Narkhede

Blood (2022) 140 (Supplement 1): 8054–8055.

https://doi.org/10.1182/blood-2022-162556

Published: 2022

Journal Articles

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age

Darcy R. Flora, Susan K. Parsons, Nicholas Liu, Kristina S. Yu, Katie Holmes, Carlos Flores, Michelle A. Fanale, Supriya Kumar, Andy Surinach, Rachel Byrd, Andrew M. Evens

Blood (2021) 138 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2021-147354

Published: 2021

Journal Articles

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma

Andrew M. Evens, Kristina S. Yu, Nicholas Liu, Andy Surinach, Katie Holmes, Carlos Flores, Supriya Kumar, Michelle A. Fanale, Darcy R. Flora, Susan K. Parsons

Blood (2021) 138 (Supplement 1): 2467.

https://doi.org/10.1182/blood-2021-152497

Published: 2021

Journal Articles

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

Susan K. Parsons, Kristina S. Yu, Nicholas Liu, Supriya Kumar, Michelle A. Fanale, Katie Holmes, Carlos Flores, Andy Surinach, Darcy R. Flora, Andrew M. Evens

Blood (2021) 138 (Supplement 1): 1390.

https://doi.org/10.1182/blood-2021-151143

Published: 2021

Journal Articles

Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Tycel J. Phillips, MD, Kristina Yu-Isenberg, PhD MPH, RPh, Nicholas Liu, PharmD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Michelle A. Fanale, MD, John M. Burke, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140534

Published: 2020

Journal Articles

Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

John M. Burke, MD, Nicholas Liu, PharmD, Kristina Yu-Isenberg, PhD MPH, RPh, Michelle A. Fanale, MD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Tycel J. Phillips, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-140832

Published: 2020

Journal Articles

Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Felipe Castro, Andy Surinach, MPH, Aino Launonen, Per-Olof Thuresson, Federico Felizzi

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-137529

Published: 2020

Journal Articles

Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States

Ashwini Shewade, Adam J Olszewski, MD, Nelson Pace, Andy Surinach, MPH, Gila Sellam, Lars Mueller, Carol O'Hear

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-136271

Published: 2020

Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD

Blood (2019) 134 (Supplement_1): 2917.

https://doi.org/10.1182/blood-2019-123664

Published: 2019

Journal Articles

Relationship Between Lenalidomide Dose Modification and Outcomes in Patients with Myelodysplastic Syndromes

Amy E. DeZern, MD MHS, Gary Binder, Albert Fliss, PhD, X. Henry Hu, MD PhD, Syed Rizvi, MD, Frank A. Corvino, Steven R. Arikian, MD, Andy Surinach, Jianyi Lee, B. Douglas Smith, MD

Blood (2015) 126 (23): 3286.

https://doi.org/10.1182/blood.V126.23.3286.3286

Published: 2015

Journal Articles

Patterns of Total Costs of Care over Time for Patients with Multiple Myeloma (MM)

Steven R Arikian, Gary Binder, Craig Gibson, X Henry Hu, Yasir Nagarwala, Mohamad A. Hussein, Frank A. Corvino, Jianyi Lee, Andy Surinach, Satyin Kaura, Saad Usmani

Blood (2015) 126 (23): 3294.

https://doi.org/10.1182/blood.V126.23.3294.3294

Published: 2015

Journal Articles

Relationship Between Lenalidomide Dose Modification and Time to Next Treatment in Newly Diagnosed Multiple Myeloma Patients

Saad Z. Usmani, MD, Gary Binder, Dejan Milentijevic, X Henry Hu, Yasir Nagarwala, Frank A. Corvino, Steven R. Arikian, Andy Surinach, William N. Harwin

Blood (2014) 124 (21): 2655.

https://doi.org/10.1182/blood.V124.21.2655.2655

Published: 2014

Journal Articles

Patterns of Total Costs of Care for Newly Diagnosed Multiple Myeloma (MM) Patients

Steven R. Arikian, Dejan Milentijevic, Gary Binder, Mara Silvia Monzini, X Henry Hu, Yasir Nagarwala, Mohamad A. Hussein, MD, Frank A. Corvino, Andy Surinach, Saad Z. Usmani, MD

Blood (2014) 124 (21): 2656.

https://doi.org/10.1182/blood.V124.21.2656.2656

Published: 2014

NARROW

Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States

Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

Relationship Between Lenalidomide Dose Modification and Outcomes in Patients with Myelodysplastic Syndromes

Patterns of Total Costs of Care over Time for Patients with Multiple Myeloma (MM)

Relationship Between Lenalidomide Dose Modification and Time to Next Treatment in Newly Diagnosed Multiple Myeloma Patients

Patterns of Total Costs of Care for Newly Diagnosed Multiple Myeloma (MM) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only